Leerink Partnrs Reiterates Outperform Rating for Morphic (NA

Leerink Partnrs reaffirmed their outperform rating on shares of Morphic (NASDAQ:MORF – Free Report) in a report issued on Monday, PriceTargets.com reports. Leerink Partnrs also issued estimates for Morphic’s Q3 2023 earnings at ($0.82) EPS, Q4 2023 earnings at ($0.85) EPS, FY2023 earnings at ($3.48) EPS, FY2024 earnings at ($4.18) EPS, FY2025 earnings at ($4.45) […]

Related Keywords

, Marc Schegerin , Leerink Partnrs , Praveenp Tipirneni , Stifel Nicolaus , Group One Trading , Metlife Investment Management , Jpmorgan Chase Co , Securities Exchange Commission , Nasdaq , Berenberg Bank , Morphic Holding Inc , York Mellon Corp , Free Report , Moderate Buy , Get Free Report , Exchange Commission , New York Mellon Corp , Life Investment Management , Rhumbline Advisers , Morphic Daily , Amorphic , Nasdaq Morf , Smorf , Medical , Reiterated Rating ,